{"id":"NCT00263575","sponsor":"Kyowa Kirin Co., Ltd.","briefTitle":"Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients","officialTitle":"A Multiple-Dose, Non-Randomized, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Effectiveness of EN3267 in the Treatment of Breakthrough Pain in Cancer Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2008-12","completion":"2009-01","firstPosted":"2005-12-09","resultsPosted":"2020-11-19","lastUpdate":"2024-06-18"},"enrollment":139,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pain","Cancer"],"interventions":[{"type":"DRUG","name":"EN3267","otherNames":["Fentanyl"]}],"arms":[{"label":"sublingual fentanyl tablet","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety and effectiveness of EN3267 in treating breakthrough pain episodes in opioid cancer patients who are using stable doses of opioid medication.","primaryOutcome":{"measure":"Evaluate the Long-term Safety and Effectiveness of EN3267","timeFrame":"screening, 2 week titration period and 12 monthly study visits","effectByArm":[{"arm":"Titration","deltaMin":64,"sd":null},{"arm":"Maintenance","deltaMin":87,"sd":null},{"arm":"Overall","deltaMin":116,"sd":null}],"pValues":[]},"eligibility":{"minAge":"17 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["21208151"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":46,"n":139},"commonTop":["Nausea","Fatigue","Vomiting","Dehydration","Edema peripheral"]}}